Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKesson
Medtronic
Express Scripts
Colorcon

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AG-120


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for AG-120?

AG-120 is an investigational drug.

There have been 16 clinical trials for AG-120. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and Leukemia, Myeloid. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Cancer Institute (NCI), and Celgene Corporation.

There are three US patents protecting this investigational drug and sixty-one international patents.

Recent Clinical Trials for AG-120
TitleSponsorPhase
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI)Phase 2
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid LeukemiaAgios PharmaceuticalsPhase 1
Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid LeukemiaNational Cancer Institute (NCI)Phase 1

See all AG-120 clinical trials

Clinical Trial Summary for AG-120

Top disease conditions for AG-120
Top clinical trial sponsors for AG-120

See all AG-120 clinical trials

US Patents for AG-120

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-120   Start Trial Therapeutically active compositions and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
AG-120   Start Trial Therapeutically active compositions and their methods of use AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
AG-120   Start Trial Pharmaceutical compositions of therapeutically active compounds AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-120

Drugname Country Document Number Estimated Expiration Related US Patent
AG-120 Argentina 089768 2032-01-19   Start Trial
AG-120 Australia 2013211436 2032-01-19   Start Trial
AG-120 Australia 2017265100 2032-01-19   Start Trial
AG-120 Canada 2861556 2032-01-19   Start Trial
AG-120 Chile 2014001891 2032-01-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Harvard Business School
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.